<DOC>
	<DOC>NCT01263327</DOC>
	<brief_summary>This phase I clinical study was designed to evaluate the safety of novel recombinant HPV 16/18 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women 18-55 years of age at enrolment. Approximately 30 study subjects will receive the novel HPV vaccine administered intramuscularly according to a 0-1-6 month schedule.</brief_summary>
	<brief_title>Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written informed consent from the subject prior to enrolment; Female between, and including, 18 and 55 years of age at the time of enrolment; Subjects must be free of obvious health problems; Not pregnant and having no plan for pregnancy; Pregnant or breastfeeding or having plan for pregnancy during the whole study (Month 07); Previous vaccination against HPV; Having severe allergic history or other immunodeficiency; Chemotherapy and other immunosuppressive agents using;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>human papillomavirus vaccine</keyword>
</DOC>